Menu

Exclusive: AIDS Healthcare Foundation Says Re-Opening 340B Law Over Contract Pharmacy Fight Will Backfire

Tom Mirga, Editor at Large 340B Report Views
An AIDS Healthcare Foundation activist handed out Let it B signs supporting the 340B program during a September 2021 protest in front of U.S. Rep. Scott Peters' (D-Calif.) district office in San Diego.

AIDS Healthcare Foundation (AHF) today criticized efforts to introduce federal legislation to address drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies. It said the drug industry “will certainly use any legislation as an opportunity to

…
Read More »

With Planned Series of House Speeches Delayed, GOP Lawmaker Speaks Out in Support of 340B

Ron Shinkman 340B Report Views
U.S. Rep Jake LaTurner (R-Kan.) praised 340B on the House floor Tuesday. An hour's worth of other testimonials by House members planned for the same day was postponed.

A Kansas Republican congressman on Tuesday urged fellow House members in a brief floor speech to “reaffirm our commitment to protecting” the 340B program.

Rep. Jake LaTurner (R-Kan.) congratulated 340B on its 30th anniversary. He said the program

…
Read More »

Biden and Becerra Slated to Speak at NACHC Event Next Week

Tom Mirga, Editor at Large 340B Report Views
President Joe Biden (left) and HHS Secretary Xavier Becerra are scheduled to speak on Monday, Feb. 14, during the National Association of Community Health Centers’ (NACHC) Policy and Issues Virtual Forum.

President Joe Biden and U.S. Health and Human Services (HHS) Secretary Xavier Becerra are scheduled to speak on Monday, Feb. 14, during the National Association of Community Health Centers’ Policy and Issues Virtual Forum, NACHC announced on Tuesday.

…
Read More »

GSK Providing Refunds for 340B Overcharges During Q1 2020

Tom Mirga, Editor at Large 340B Report Views
GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

Drug manufacturer GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

GSK posted a public notice about the repayments on the U.S. Health Resources and Services Administration web

…
Read More »

HRSA Says at Least Three Hospitals Have Lost 340B Eligibility So Far Due to COVID-19 Patient Mix Changes

Tom Mirga, Editor at Large 340B Report Views
St. Elizabeth Healthcare in Ft. Thomas, Ky., is one of three hospitals known to have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. More are expected to lose eligibility soon.

The U.S. Health Resources and Services Administration (HRSA) said yesterday it knows of three hospitals that have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. There

…
Read More »

Democratic Senator’s Illness Stalls Action on Drug Pricing Indefinitely

Tom Mirga and Ron Shinkman, Editor at Large 340B Report Views
Sen. Ben Ray Lujan's (D-N.M.) recent stroke and absence makes it even less likely that Congress will pass Democratic drug pricing legislation any time soon.

Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.

Lujan’s chief of

…
Read More »

Second Major 340B Stakeholder Says Congress May Need to Stop Drug Makers’ Contract Pharmacy Actions

Tom Mirga, Editor at Large 340B Report Views
NACHC is the second major 340B covered entity group in recent days to say publicly that Congress might need to resolve the impasse over 340B contract pharmacy.

The National Association of Community Health Centers (NACHC) told Republican members of Congress last week that “congressional action may be the only solution” to drug makers’ “aggressive actions to limit patients’ access to affordable medications at contract pharmacies.”

…
Read More »

Apexus Picks Ohio Health System Pharmacy Exec Michelle Wiest For Influential 340B Position

Tom Mirga, Editor at Large 340B Report Views
Apexus announced yesterday that it has hired Michelle Wiest, most recently vice president of pharmacy services at UC Health in Cincinnati, to be its senior vice president of 340B policy and compliance.

Michelle Wiest, most recently vice president of pharmacy services at UC Health in Cincinnati, is Apexus’s new senior vice president of 340B policy and compliance.

Apexus announced Wiest’s hiring yesterday. The company said Wiest will oversee its education

…
Read More »

ICER Says Four Drugs Are Cost-Effective in Keeping COVID-19 Patients Out of Hospitals

Ron Shinkman 340B Report Views
The Institute for Clinical and Economic Review has tentatively concluded that four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients.

The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients. The independent nonprofit group evaluates prescription drugs and medical treatments’ cost

…
Read More »

Despite Initial Optimism, Rural Hospitals Won’t Benefit from 340B Pricing on BMS’s Myeloma Drugs

Tom Mirga, Editor at Large 340B Report Views
340B Report Investigative Series text over magnifying glass and pile of various pills
Rural and free-standing cancer hospitals will not get access to voluntary 340B pricing on Bristol Myers Squibb’s expensive myeloma drugs Revlimid, Pomalyst, and Thalomid under a policy change the company announced last month.

Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.

…
Read More »

Site Footer Live